Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

Meeting Coverage > Psych Congress Esketamine Also Effective Without Adjunctive Antidepressant — Trial data may expand use, with "opportunity to truly individualize treatment" by Kristen Monaco ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression.

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.

Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca) for treatment-resistant depression, results of a multicenter, head-to-head phase 3 ...

Psychiatry > General Psychiatry 1 in 5 Adults Report Anxiety, Depression; Esketamine Label Update; Autism Dx Up 175% — News and commentary from the psychiatry world by Kristen Monaco, Senior ...

Esketamine, the (S) enantiomer of racemic ketamine, is FDA-approved for adults with TRD and adults with MDD with suicidal thoughts or actions in combination with an oral antidepressant.

Topline results were announced from a phase 3b trial that compared the short- and long-term efficacy, safety, and tolerability of esketamine nasal spray to quetiapine extended-release (XR) in ...

Esketamine-treated women had lower EPDS scores on day 7 and day 42 (median difference, -3). Individuals receiving esketamine also had reduced HDRS scores 42 days after delivery (mean difference, -4).